CoChat

Ketamine Metabolite (2 R,6 R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors

Open access

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

values congruous with our simulations. Overall, our findings are consistent with opioid pathway involvement in ketamine function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acschemneuro.0c00741

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (a) Key residue interactions of protonated HNK in MOR and KOR. In each case, the ligand is in the orthosteric binding pocket. Note the presence of D3.32 (with hydrogen bond) and H6.52. See Supporting Table 2 for comprehensive list of nearby residues. (b) Root mean square deviation (RMSD) of ligand over simulation time in equilibrium MD simulations prior to FEP, for HNK. Plots for all ligands as well as receptor pocket available in the Supporting Information. (c) ΔG vs lambda plots of ligand–protein decoupling FEP simulations for HNK, both neutral (left) and protonated (right), illustrating the smoothness of these curves, which are representative of all FEP simulations. Calculations for MOR and KOR as well as both binding pocket His protonation states are shown. Forward and backward legs of these interleaved double-wide sampled simulations are shown. More detailed plots, where each curve is labeled, are available in the Supporting Information.
Figure 1 (a) Key residue interactions of protonated HNK in MOR and KOR. In each case, the ligand is in the orthosteric binding pocket. Note the presence of D3.32 (with hydrogen bond) and H6.52. See Supporting Table 2 for comprehensive list of nearby residues. (b) Root mean square deviation (RMSD) of ligand over simulation time in equilibrium MD simulations prior to FEP, for HNK. Plots for all ligands as well as receptor pocket available in the Supporting Information. (c) ΔG vs lambda plots of ligand–protein decoupling FEP simulations for HNK, both neutral (left) and protonated (right), illustrating the smoothness of these curves, which are representative of all FEP simulations. Calculations for MOR and KOR as well as both binding pocket His protonation states are shown. Forward and backward legs of these interleaved double-wide sampled simulations are shown. More detailed plots, where each curve is labeled, are available in the Supporting Information.CC BY-NC-ND · PubMed Central
Figure 2 Bar plots of binding affinities of ketamine and metabolites with opioid receptors. These figures include the cost of desolvation from aqueous solution and binding to the receptor.
Figure 2 Bar plots of binding affinities of ketamine and metabolites with opioid receptors. These figures include the cost of desolvation from aqueous solution and binding to the receptor.CC BY-NC-ND · PubMed Central
Figure 3 Sigmoidal dose–response inhibition curves from [35S]GTPγS assays, including standard deviations. Increasing concentrations of HNK depress activation in both MOR and KOR, suggesting an inverse agonist effect. This is attenuated by pretreatment with naltrexone in both MOR and KOR.
Figure 3 Sigmoidal dose–response inhibition curves from [35S]GTPγS assays, including standard deviations. Increasing concentrations of HNK depress activation in both MOR and KOR, suggesting an inverse agonist effect. This is attenuated by pretreatment with naltrexone in both MOR and KOR.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. Cohen M. L., 1974, J. Pharmacol. Exp. Ther., 189, 351

Cited by

See all 28

Metadata

Authors
Joseph, T. T., Bu, W., Lin, W., Zoubak, L., Yeliseev, A., Liu, R., Eckenhoff, R. G., & Brannigan, G.
Affiliations
  • University of Pennsylvania (US)
  • Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
  • National Institutes of Health (US)
  • Rutgers, The State University of New Jersey (US)
Corresponding author
Joseph, Thomas T.
Venue
ACS Chemical Neuroscience
Published
2021-04-27
Volume
12
Issue
9
Pages
1487-1497
ISSN
1948-7193 (ISSN-L)
OpenAlex
W3157868786
Cited by
28
References
60
Citations by year
2026: 5 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 2
FWCI
2.07
Type
journal article
Language
en
Open access
Locations
  • ACS Chemical Neuroscience (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Foundation for Anesthesia Education and Research
  • National Institute on Alcohol Abuse and Alcoholism
  • National Institute of General Medical Sciences (K08GM139031, R01GM111421, T32GM112596)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
ketamine metabolites, (2R,6R)-hydroxynorketamine, mu-opioid receptor, kappa opioid receptor, opioid receptor interaction, molecular docking
MeSH terms
Antidepressive Agents, Depression, Ketamine, Receptors, Opioid, kappa

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketamine Metabolite (2 R,6 R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors. https://app.cochat.ai/papers/10.1021/acschemneuro.0c00741
The paper
Joseph, T. T., Bu, W., Lin, W., Zoubak, L., Yeliseev, A., Liu, R., Eckenhoff, R. G., & Brannigan, G. (2021). Ketamine Metabolite (2 R,6 R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.0c00741

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.